Episodes

  • Pure Global: Brazil's Sudden SaMD Shockwave - The Unforeseen ANVISA Cybersecurity Mandate

    Pure Global: Brazil's Sudden SaMD Shockwave - The Unforeseen ANVISA Cybersecurity Mandate
    Apr 1 2026
    In this episode, we dissect a sudden and critical regulatory update from Brazil's ANVISA that was issued just last week. The new instruction imposes stringent cybersecurity and data handling requirements on all Software as a Medical Device (SaMD) and connected devices, catching many international manufacturers off guard and putting existing market approvals at risk. We explore the specific technical and documentation changes now required, from mandatory penetration testing to new data localization rules. This shift forces companies to rethink their entire compliance and operational strategy for Latin America's largest market. A case in point: A successful foreign manufacturer of remote patient monitoring tools, already established in Brazil, now faces an urgent compliance crisis. Their current registration is invalid, and they must rapidly re-engineer their product's data architecture and conduct a full cybersecurity audit to avoid being forced off the market. This is a costly and complex challenge that could halt their regional revenue stream. Key Takeaways: * What are the specific cybersecurity demands in ANVISA's new instruction for connected devices? * Do your existing products in Brazil now face an immediate compliance gap? * How will the new data localization rules impact your operational costs and IT infrastructure? * What is the new role and liability of local importers in ensuring device cybersecurity? * Are you prepared for a complete technical dossier re-submission for your software-based devices? * Why is Brazil making this sudden move, and which countries in LATAM are likely to follow? * How can this regulatory hurdle be turned into a competitive advantage? Struggling to keep up with unpredictable regulatory changes in LATAM? Pure Global offers end-to-end regulatory consulting, leveraging local expertise and advanced AI to streamline market access. Whether it's navigating Brazil's new cybersecurity rules or expanding into Mexico and Colombia, we act as your local representative to secure and maintain your market presence. Contact us for a strategic consultation at info@pureglobal.com or visit https://pureglobal.com/.
    Show more Show less
    2 mins
  • Brazil's AI Gold Rush: Navigating the LGPD Data Maze with Pure Global

    Brazil's AI Gold Rush: Navigating the LGPD Data Maze with Pure Global
    Mar 31 2026
    Brazil's medical device authority has just unveiled a new framework for AI technologies, signaling a gold rush for innovators in the region. This new resolution promises a clearer path to market for cutting-edge software as a medical device, opening doors to Latin America's largest healthcare economy. But hidden within this opportunity is a critical challenge that could stop foreign companies in their tracks. The regulation mandates strict adherence to Brazil's General Data Protection Law (LGPD), a complex and demanding data privacy standard. This episode of LATAM MedTech Insights unpacks the new AI resolution, exposing the hidden compliance traps and what it really takes to succeed in this promising market. **A Case Study in Foresight:** An American AI diagnostic firm sees the news from Brazil and fast-tracks its expansion plan. Their device, already FDA-cleared, seems like a perfect fit. But their submission is quickly flagged. The reason? Their cloud data processing is handled on servers in the United States, a direct violation of the unwritten expectation of LGPD compliance for local data handling. Their market entry is now frozen, facing the unexpected and costly decision of whether to build new data infrastructure just for one market. **Key Takeaways:** * What is CFM Resolution 2,454/2026 and why is it more than just an approval pathway? * How does Brazil's LGPD law create a unique regulatory hurdle for AI medical devices? * Why might your global data strategy be incompatible with the Brazilian market? * What are the potential costs associated with data localization for MedTech companies? * How can a "privacy-by-design" approach give you a competitive advantage in Brazil? * What are the key differences between LGPD and GDPR that you must know? * Why is understanding the local regulatory culture just as important as reading the rules? At Pure Global, we specialize in navigating these complex regulatory landscapes. We offer end-to-end solutions, from developing your regulatory strategy to acting as your local representative in Brazil and over 30 other markets. Our combination of local expertise and advanced AI tools streamlines your path to market access. Don't let regulatory hurdles block your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.
    Show more Show less
    2 mins
  • Pure Global: Brazil's AI Rulebook - Cracking the New Medical AI Framework

    Pure Global: Brazil's AI Rulebook - Cracking the New Medical AI Framework
    Mar 30 2026
    In this episode, we dive into the landmark new resolution from Brazil’s Federal Council of Medicine (CFM) that creates a specific regulatory framework for Artificial Intelligence in medicine. This is a pivotal moment for digital health in Latin America, establishing new rules for physician oversight, data privacy, and the responsibilities of technology providers. We explore the immediate impact on MedTech and IVD manufacturers aiming to launch AI-powered solutions in the Brazilian market. This isn't just a guideline for doctors. it's a new set of requirements for the tools they use. We break down what this means for product design, technical documentation, and your overall market access strategy in Brazil. **Case Study:** A European MedTech firm has a powerful AI diagnostic software for radiology. They considered Brazil a prime market but were operating in a grey area. Now, the CFM resolution provides a path, but one with new obstacles. How must they adapt their AI's user interface to meet the "human oversight" mandate, and how can they prove their data processing is fully compliant with Brazil's stringent LGPD privacy law without a costly redesign? **Key Takeaways:** - How does the CFM's focus on physician liability change your product's risk management file? - Is your AI's algorithm explainable enough to meet the new transparency requirements? - What specific steps must you take to ensure your data practices are compliant with both the CFM resolution and Brazil's LGPD? - How will you need to modify your training and support materials for Brazilian medical professionals? - Does this new resolution require a separate clinical validation study for the Brazilian population? - How could this physician-centric framework in Brazil influence future AI regulations in other LATAM countries? At Pure Global, we offer end-to-end regulatory consulting solutions for Medical Technology and In-Vitro Diagnostic companies. We combine local expertise with advanced AI and data tools to streamline your global market access, including navigating complex new frameworks like Brazil's AI regulations. To get your product to market efficiently and correctly, contact us at info@pureglobal.com or visit https://pureglobal.com/.
    Show more Show less
    2 mins
  • Brazil's AI Fast-Track: Pure Global on Cracking ANVISA's 90-Day Approval Code.

    Brazil's AI Fast-Track: Pure Global on Cracking ANVISA's 90-Day Approval Code.
    Mar 29 2026
    This week on LATAM MedTech Insights, we dive into the seismic shift in Brazil's digital health market. ANVISA just launched its 'Agiliza-IA' program, promising to approve AI-powered diagnostic software in a record 90 days. This could unlock one of the largest markets in Latin America for SaMD innovators. But there's a catch. While the speed is tempting, the program introduces formidable new barriers. Consider a European company with a market-leading AI tool. They're ready to enter Brazil, but now face an unexpected demand for clinical trials conducted exclusively on Brazilian patients. This single requirement could delay their entry by a year and cost millions. Is the fast-track worth the price? Key Takeaways: - What exactly is ANVISA's new "Agiliza-IA" program? - Why are the new local clinical data requirements a game-changer for foreign companies? - What are the specific cybersecurity protocols you must now meet for approval? - How did a local startup beat global giants to the first approval? - Is Brazil's 90-day promise a real opportunity or a hidden trap? - What does this mean for the future of MedTech regulation across LATAM? - How can you start preparing your technical dossier for this new pathway today? At Pure Global, we specialize in turning these regulatory puzzles into market access victories. We offer end-to-end consulting for MedTech and IVD companies, leveraging local expertise and advanced AI tools to streamline your entry into over 30 global markets, including Brazil. Don't let complex regulations be a barrier to your growth. Contact Pure Global at info@pureglobal.com or visit us at https://pureglobal.com/ to learn how we can accelerate your journey.
    Show more Show less
    2 mins
  • Pure Global: Brazil's New MedTech Shortcut & ANVISA's Hidden Compliance Toll.

    Pure Global: Brazil's New MedTech Shortcut & ANVISA's Hidden Compliance Toll.
    Mar 28 2026
    This week, we dive into a landmark regulatory shift in Brazil. ANVISA has just unveiled a new "Reliance" pathway, promising an incredible 80% reduction in review time for medical devices already approved by MDSAP authorities. This could dramatically accelerate market access for many international firms. However, this new shortcut comes with a critical catch. At the same time, ANVISA has implemented stricter, IMDRF-aligned standards for essential safety and performance requirements. This means the technical documentation bar has been raised significantly, potentially creating new hurdles even for experienced manufacturers. We break down the opportunity and the hidden challenge. We explore the case of a U.S. orthopedic implant company, whose dream of a fast-track approval was met with the harsh reality of a complete technical file overhaul, forcing them to navigate the gap between their existing FDA compliance and Brazil's new, tougher standards. This week, you'll learn: - What are the exact eligibility criteria for ANVISA's new Reliance pathway? - How does the new RDC 848 resolution change your technical documentation checklist forever? - Which common gaps exist between an FDA-approved file and the new IMDRF-based requirements? - Is the Reliance pathway a guaranteed approval, or are there still hidden pitfalls? - What is the first step your company should take right now to adapt to this new landscape? - How can you leverage your existing international approvals most effectively for the Brazilian market? - What are the critical risk management updates required under the new regulations? Navigating the complexities of global markets is our expertise. At Pure Global, we provide end-to-end regulatory consulting for MedTech and IVD companies, using local expertise and advanced data tools to streamline your market access. Whether it's adapting your technical dossier for Brazil's new standards or acting as your local representative, we clear the path for your innovation. Contact us at info@pureglobal.com or visit https://pureglobal.com/.
    Show more Show less
    2 mins
  • Brazil's AI MedTech Crackdown: Pure Global on ANVISA's New Cybersecurity Demands

    Brazil's AI MedTech Crackdown: Pure Global on ANVISA's New Cybersecurity Demands
    Mar 27 2026
    Brazil's MedTech landscape is shifting. A quiet but powerful new technical note from ANVISA has just redefined the rules for AI-powered medical devices, creating immediate hurdles for global manufacturers. This update directly links cybersecurity and data privacy to the core of the device approval process, impacting all new and pending registrations. In this episode, we dissect the three critical areas of this clarification, from new clinical data expectations to the now-mandatory Software Bill of Materials (SBOM). We explore how ANVISA is tightening its alignment with Brazil's General Data Protection Law (LGPD) and what it means for your technical dossier. This is essential listening for any innovator looking to enter or expand within Latin America's largest market. Case Study Spotlight: Imagine your cutting-edge AI diagnostic software is deep into the ANVISA review process, and your launch in Brazil seems imminent. Suddenly, your application is stalled by a list of unexpected technical questions about cybersecurity monitoring and LGPD compliance, topics your initial submission only briefly touched upon. Your team must now scramble to produce new documentation that meets these unwritten rules, delaying your market entry by months and putting you behind competitors. What’s your next move. Key Takeaways: - What are the three most critical changes in ANVISA's new interpretation of AI SaMD regulations. - How does this technical note immediately affect your pending medical device submission in Brazil. - Why has a Software Bill of Materials (SBOM) suddenly become essential for approval. - Is your current cybersecurity plan robust enough to satisfy both ANVISA and Brazil's LGPD. - What specific documentation do you need to prepare now to avoid registration delays. - How can you transform this new regulatory challenge into a powerful competitive advantage. At Pure Global, we specialize in navigating these complex and evolving regulatory landscapes. Our team of local experts in Brazil, combined with advanced AI and data tools, provides end-to-end solutions to ensure your MedTech and IVD products achieve and maintain market access. From initial regulatory strategy and dossier submission to post-market surveillance, we streamline your path into over 30 global markets. Don't let unexpected regulatory shifts derail your expansion. Contact Pure Global at info@pureglobal.com or visit https://pureglobal.com/ to secure your market presence.
    Show more Show less
    2 mins
  • Pure Global: Mexico's FDA Fast-Track - The COFEPRIS Secret Handshake for 510(k) Devices

    Pure Global: Mexico's FDA Fast-Track - The COFEPRIS Secret Handshake for 510(k) Devices
    Mar 26 2026
    Last week, Mexico's regulatory body, COFEPRIS, enhanced its partnership with the U.S. FDA, launching a new phase of its fast-track program for medical devices. This creates an accelerated approval pathway for devices already cleared in the United States, representing a landmark shift in the region's regulatory landscape. This episode dissects the massive opportunity this presents, which can cut market entry timelines from years down to just months. We explore which devices qualify, the detailed submission requirements, and what "regulatory reliance" truly means for your quality and post-market surveillance strategy. **Burning Questions for This Episode:** * Which specific device categories are eligible for the new COFEPRIS-FDA fast-track program? * What exact FDA documentation is now required for a streamlined submission to COFEPRIS? * How does this reliance pathway change the responsibilities of your Mexican Registration Holder? * What are the new, immediate post-market reporting obligations under this program? * Is this accelerated pathway a sign of a permanent shift in Mexican regulatory policy? * How can you leverage your existing 510(k) or PMA to maximize this opportunity? * What are the hidden compliance risks that could disqualify you from the program? At Pure Global, we specialize in navigating these complex regulatory shifts. We offer end-to-end solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline market access in over 30 countries, including Mexico. Whether you need to prepare a dossier for this new pathway or develop a broader LATAM strategy, our team is here to help. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.
    Show more Show less
    2 mins
  • Pure Global: Brazil's MedTech Compliance & ANVISA's New Hidden Hurdles.

    Pure Global: Brazil's MedTech Compliance & ANVISA's New Hidden Hurdles.
    Mar 25 2026
    Brazil's medical device market is undergoing a seismic shift. The national regulator, ANVISA, has just released RDC 848/2024, a sweeping new resolution that redefines the essential safety and performance requirements for all medical devices and IVDs. This isn't just a simple update; it's a new paradigm that demands a total lifecycle approach to compliance and introduces stringent new rules for high-tech areas like software and cybersecurity. This episode breaks down exactly what this means for manufacturers, especially those from outside Latin America. We reveal the hidden hurdles that can derail your product launch and lead to costly delays. For example, a US-based company with FDA clearance found its market entry plan blocked overnight, needing a complete overhaul of its technical dossier to meet Brazil's new, specific cybersecurity and clinical data requirements, delaying their launch by eight months. Key Takeaways: - How does ANVISA's RDC 848/2024 impact your current Brazil registration strategy? - Are your device's cybersecurity protocols robust enough for the new, explicit requirements? - What are the biggest compliance gaps this regulation creates for devices already approved in the EU or US? - Why is a 'total lifecycle' approach to risk management now mandatory for market access in Brazil? - How can you proactively update your technical dossier to prevent rejection under these new rules? - What specific clinical evidence is now required to prove performance claims to ANVISA? - Does this new regulation affect your post-market surveillance obligations? At Pure Global, we offer end-to-end regulatory consulting solutions for MedTech and IVD companies to streamline global market access. We combine local expertise in over 30 markets, including Brazil, with advanced AI to navigate complex changes like RDC 848/2024, ensuring your path to market is efficient and successful. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.
    Show more Show less
    3 mins